Immunai IPO

immunai.com

Immuani develops solutions for oncology treatments and auto-immune disorders by utilizing AI and ML technology to assist in mapping and to provide insights into the reprogramming of the immune system.

Founded2018
Total Funding to Date$295.22MM
Register for Details

For more details on financing and valuation for Immunai, register or login.

Please provide your first name.
Please provide your last name.
Please provide a valid email address.

By registering, you agree to Forge’s Terms of Use. Already registered? Click here to log in

Immunai Ticker Symbol

Immunai does not currently have an official ticker symbol because this company is still private. Register today to connect with our Private Market Specialists and learn more about new pre-IPO investment opportunities.

Immunai Stock Price

The stock price for Immunai will be known as it becomes public. Here are similar public companies: HealthStream (NAS: HSTM), Doximity (NYS: DOCS), Zymergen (NAS: ZY), Sight Sciences (NAS: SGHT).

Major Investors for Immunai

8VC
Koch Disruptive Technologies
Icon Ventures

Immunai Funding Rounds and IPO Valuation

Date Funding Round Funding Raised Price per Share IPO Valuation
10/27/2021 Series C-1 and C-2 $1.15B $XXX.XX $XXX.XX
2/11/2021 Series B-1 and B-2 $240.97MM $XXX.XX $XXX.XX
5/14/2020 Series A, Seed-1, and Seed-2 $38.16MM $XXX.XX $XXX.XX
Based on primary financings

Other companies like Immunai in the Healthcare sector

Sector
Last Round Est. Valuation
$2.15B
Sector
Last Round Est. Valuation
$3.67B
Sector
Last Round Est. Valuation
$334.19MM
Sector
Last Round Est. Valuation
$317.32MM
Sector
Last Round Est. Valuation
$1.08B
Sector
Last Round Est. Valuation
$4.26B
Sector
 
 
Sector
Last Round Est. Valuation
$885.01MM